- Home
- CRTO vs IOVA Comparison
CRTO vs IOVA Comparison
Compare CRTO & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRTO
- IOVA
- Stock Information
- Founded
- CRTO 2005
- IOVA 2007
- Country
- CRTO France
- IOVA United States
- Employees
- CRTO N/A
- IOVA N/A
- Industry
- CRTO Advertising
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRTO Consumer Discretionary
- IOVA Health Care
- Exchange
- CRTO Nasdaq
- IOVA Nasdaq
- Market Cap
- CRTO 2.4B
- IOVA 2.6B
- IPO Year
- CRTO 2013
- IOVA N/A
- Fundamental
- Price
- CRTO $37.87
- IOVA $6.22
- Analyst Decision
- CRTO Buy
- IOVA Strong Buy
- Analyst Count
- CRTO 10
- IOVA 9
- Target Price
- CRTO $50.33
- IOVA $23.33
- AVG Volume (30 Days)
- CRTO 353.3K
- IOVA 9.3M
- Earning Date
- CRTO 02-05-2025
- IOVA 02-26-2025
- Dividend Yield
- CRTO N/A
- IOVA N/A
- EPS Growth
- CRTO 1182.57
- IOVA N/A
- EPS
- CRTO 1.63
- IOVA N/A
- Revenue
- CRTO $1,946,556,000.00
- IOVA $90,858,000.00
- Revenue This Year
- CRTO N/A
- IOVA $13,758.71
- Revenue Next Year
- CRTO $5.96
- IOVA $171.20
- P/E Ratio
- CRTO $23.50
- IOVA N/A
- Revenue Growth
- CRTO N/A
- IOVA 12751.20
- 52 Week Low
- CRTO $25.27
- IOVA $5.57
- 52 Week High
- CRTO $49.93
- IOVA $18.33
- Technical
- Relative Strength Index (RSI)
- CRTO 39.10
- IOVA 33.94
- Support Level
- CRTO $37.04
- IOVA $5.70
- Resistance Level
- CRTO $38.77
- IOVA $6.06
- Average True Range (ATR)
- CRTO 1.05
- IOVA 0.43
- MACD
- CRTO -0.09
- IOVA 0.01
- Stochastic Oscillator
- CRTO 18.05
- IOVA 19.37
About CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.